title: Phase II study of esorubicin in patients with advanced colorectal carcinoma and no prior chemotherapy: an Illinois Cancer Council Trial.
authors.forename: G Y
authors.initials: GY
authors.lastname: Locker
authors.forename: T
authors.initials: T
authors.lastname: Hoeltgen
authors.forename: L
authors.initials: L
authors.lastname: Kilton
authors.forename: S
authors.initials: S
authors.lastname: Krauss
authors.forename: M
authors.initials: M
authors.lastname: McNamara
authors.forename: R
authors.initials: R
authors.lastname: Blough
authors.forename: C
authors.initials: C
authors.lastname: Johnson
mesh_terms: D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004317:Doxorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007087:Illinois; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D004317:Doxorubicin; C030851:esorubicin